Skip Navigation LinksHome > May 2012 - Volume 28 - Issue 3 > Hepatitis C therapy update
Current Opinion in Gastroenterology:
doi: 10.1097/MOG.0b013e3283528e1e
LIVER: Edited by Don Rockey

Hepatitis C therapy update

Casey, Lisa C.; Lee, William M.

Collapse Box


Purpose of review: We review here the recent literature regarding hepatitis C treatment through January 2012. We discuss newly approved therapies and their clinical trial data and discuss what can be expected in this rapidly changing field.

Recent findings: Two new directly acting antiviral agents were approved in 2011 for use in hepatitis C treatment, bringing shortened treatment durations, and increased treatment success to some patients with genotype 1 hepatitis C. Additional drugs using different viral targets are in development to further improve response rates, tolerance, and increase access to therapy.

Summary: Telaprevir and boceprevir were approved in 2011 for use against genotype 1 hepatitis C, in combination with pegylated interferon and ribavirin. In most populations of genotype 1 patients, response rates are much improved but increased treatment related anemia has been seen. Additional options for therapy, including interferon-free regimens, are still needed and are under development.

© 2012 Lippincott Williams & Wilkins, Inc.


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.